Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
#BMS #Cobenfy #schizophrenia #psychiatry Biotech Executive, Thought Leader & Creator | Diagnostics Executive | Microfluidics & Immunoassay Innovation | FDA Strategy Led EUA 230055, EUA 240006 & 510(k) K240728 | Oncology, AIBiology & IVD Commercialization Market Watch | Bristol Myers Squibbs Cobenfy Faces Uptake Challenges Amid Strong Q3 Earnings Bristol Myers Squibb ($BMY) reported $12.2B in Q3 revenue, surpassing analyst expectations yet investor attention centered on Cobenfy, the first new schizophrenia drug in 35 years, which posted $43M in sales, slightly below forecasts
Several additional compounds deserve mention for anyone planning their long-term strategy
The long-term effects on infants, particularly with early post-partum or chronic maternal use of higher doses of semaglutide, remain unknown
While this long list may appear robust and impressive for a regular company, it seems somewhat insufficient for a top-tier pharmaceutical enterprise with a market capitalization in the hundreds of billions
.png)
US$ 22.96
US$ 27.46
US$ 22.73
